Quintiles IMS Holdings Inc (NYSE:Q) has been upgraded to Buy in a statement by TheStreet earlier today.
- Updated: October 15, 2016
Displaying a price of $77.26, Quintiles IMS Holdings Inc (NYSE:Q) traded -0.48% lower on the day. The last stock price is up 5.05% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. Q has recorded a 50-day moving average of $78.01 and a 200-day moving average of $71.72. 707,026 shares of the stock were exchanged, down from an average trading volume of 1,095,290
TheStreet has upgraded Quintiles IMS Holdings Inc (NYSE:Q) to Buy in a statement released on 10/10/2016.
Previously on Tuesday October 11, 2016, Zacks Investment Research reported about Quintiles IMS Holdings Inc (NYSE:Q) upped the target price from $0.00 to $89.00 that suggested an upside of 0.12%.
See Chart Below
Quintiles IMS Holdings Inc has PE ratio of 22.65 with a one year low of $55.01 and a one year high of $81.45 and has a total market value of $0.
A total of 15 equity analysts have released a ratings update on Q. Eight analysts rating the company a strong buy, nine analysts rating the company a buy, two analysts rating the company a hold, zero firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $76.50.
About Quintiles IMS Holdings Inc (NYSE:Q)
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.